title: [A study on human T cells bearing IgG-Fc receptor in patients with bladder tumor].
abstract: IgG-FcR+-T cell ratio was measured in 50 patients with bladder tumor as a parameter to estimate the cell mediated immunity before the treatment. IgG-FcR+-T cell was detected by the double rosette method, employing sheep erythrocytes and rabbit IgG antibody coated chicken erythrocytes. IgG-FcR+-T cell ratio in 50 patients with bladder tumor was 7.6 +/- 5.7% (mean +/- standard deviation), while that in controls consisting of 20 patients with other diseases but bladder tumor was 5.2 +/- 2.4%. There was no significant difference between them. IgG-FcR+-T cell ratio in the group in early stages (pTa, pT1 & pT2) was 5.4 +/- 4.5%, and that in the group in advanced stages (pT3a, pT3b & pT4) was 10.8 +/- 6.0%.--significant difference between them (p less than 0.001)--. IgG-FcR+-T cell ratio in the low graded group (G0 & G1) was 5.5 +/- 4.4% and that in the high graded group (G2 & G3) was 9.7 +/- 6.2%.--significant difference between them (p less than 0.01)--. IgG-FcR+-T cell ratio in patients with the serum level of CEA over 2.6 ng/ml was 12.5 +/- 6.3% and that under 2.5 ng/ml was 5.6 +/- 3.7%.--significant difference between them (p less than 0.001)--. In patients having IgG-FcR+-T cell ratio over 9%, there was a correlation between IgG-FcR+-T cell ratio and PHA-induced lymphocyte blastogenesis ratio (r = -0.81, p less than 0.01). In patients with the serum level of CEA over 2.6% ng/ml, PHA-induced lymphocyte blastogenesis was decreased significantly and IgG-FcR+-T cell ratio was increased significantly. These findings suggest that serum CEA may play a role to proliferate the IgG-FcR+-T cells in association with an inhibition of PHA-induced lymphocyte blastogenesis.
authors.forename: T
authors.initials: T
authors.lastname: Fujiwara
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000943:Antigens, Differentiation; D002272:Carcinoembryonic Antigen / Q000032:analysis; D005260:Female; D006801:Humans; D007111:Immunity, Cellular; D007074:Immunoglobulin G / Q000378:metabolism*; D008213:Lymphocyte Activation; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D011961:Receptors, Fc / Q000032:analysis*; D017452:Receptors, IgG; D013601:T-Lymphocytes / Q000276:immunology* / Q000378:metabolism; D001749:Urinary Bladder Neoplasms / Q000276:immunology* / Q000473:pathology
chemical_list: D000943:Antigens, Differentiation; D002272:Carcinoembryonic Antigen; D007074:Immunoglobulin G; D011961:Receptors, Fc; D017452:Receptors, IgG